XOMA Royalty Acquires LAVA Therapeutics, Completes $1.04 Cash Per Share Deal.

XOMA Royalty Corporation has acquired all common shares of LAVA Therapeutics for $1.04 per share in cash and a non-transferrable contingent value right. The CVR represents 75% of net proceeds from LAVA's partnered assets and unpartnered programs, as well as up to $0.23 per CVR for potential liabilities. The acquisition adds two early-stage bispecific antibody programs to XOMA's portfolio.